The notions of individual and collective ethics were first explicitly defined in the biostatistical literature in 1971 to motivate a mathematical solution to a posed ethical dilemma. This paper reviews key antecedents to these concepts and traces explicit references to them over time, primarily in the biostatistical literature. Following a historical exposition of these texts, a critical thematic analysis shows the following: the normative force of these concepts has not been adequately argued. Individual and collective ethics do not solve the problem of how to use accumulating data to inform ethical action. The notions of the “individual” and the “collective” are too vague to prompt clear moral imperatives, especially in difficult cases. These concepts have not been successfully linked to a standard ethical framework. Finally, the paper concludes with the observation that a systematic, comprehensive ethical framework must be identified to fulfill the intuitions behind individual and collective ethics.
Get full access to this article
View all access options for this article.
References
1.
1. Lellouch J, Schwartz D. L'essai thérapeutique: éthique individuelle oúthique collective? [The clinical trial: individual ethics or collective ethics?]Revue de l’Institut International de Statistique1971; 39: 127-136.
2.
2. Colton T. A model for selecting one of two medical treatments. Journal of the American Statistical Association1963; 58: 388-400.
3.
3. Anscombe FJ. Sequential medical trials. Journal of the American Statistical Association1963; 58: 365-383.
4.
4. Cornfield J, Halperin M, Greenhouse SW.An adaptive procedure for sequential clinical trials. Journal of the American Statistical Association1969; 64: 759-770.
5.
5. Canner PL. Selecting one of two treatments when the responses are dichotomous. Journal of the American Statistical Association1970; 65: 293-306.
6.
6. Hill AB. Medical ethics and controlled trials. British Medical Journal1963; 1: 1043-1149.
7.
7. Armitage P. Sequential Medical Trials. Springfield, IL: Charles C. Thomas, 1960.
8.
8. Armitage P. Sequential medical trials: some comments on F. J. Anscombe's paper. Journal of the American Statistical Association1963; 58: 384-387.
9.
9. Zelen M. Play the winner rule and the controlled clinical trial. Journal of the American Statistical Association1969; 64: 131-146.
10.
10. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. Journal of Chronic Diseases1967; 20: 637-648.
11.
11. Schwartz D, Flamant R, Lellouch J. L'essai thérapeutique chez l’homme. Paris: Flammarion médecine-sciences, 1970.
12.
12. Schwartz D, Flamant R, Lellouch J. Clinical trials. New York: Academic Press, 1980.
13.
13. Sancho H, Hayat M. Are controlled clinical trials unnecessary?Biomedicine1973; 18: 173-176.
14.
14. Weinstein MC. Allocation of subjects in medical experiments. New England Journal of Medicine1974; 291: 1278-1185.
15.
15. Burkhardt R, Kienle G. Controlled clinical trials and medical ethics. Lancet1978; 1604: 1356-1159.
16.
16. Burkhardt R, Kienle G. Controlled clinical trials and the importance of medical judgment. In Tagnon HJ, Staquet MJ eds. Controversies in cancer: design of trials and treatment. New York: Masson Publishing USA, 1979: 31-35.
17.
17. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Adopted 18th WMA General Assembly, Helsinki, Finland, June 1964; amended 29th WMA General Assembly, Tokyo, Japan, October 1975; 35th WMA General Assembly, Venice, Italy, October 1983; 41st WMA General Assembly, Hong Kong, September 1989; 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996; and 52nd WMA General Assembly, Edinburgh, Scotland, October 2000; Note of Clarification on Paragraph 29 added by the WMA General Assembly, Washington 2002. Note of Clarification on Paragraph 30 added by the WMA General Assembly, Tokyo 2004. Available from: http://www.wma.net/e/policy/b3.htm (accessed 22 April 2005).
18.
18. Tubiana M. Judgment and decision in oncology. Bulletin du Cancer1980; 67: 369-373.
19.
19. Armitage P. Clinical trials in the secondary prevention of myocardial infarction and stroke. Thrombosis and Haemostasis1980; 43: 90-94.
20.
20. Vere D. Controlled clinical trials: the current ethical debate. Journal of the Royal Society of Medicine1981; 74: 85-88.
21.
21. Jeanneret O, Raymond L. Aspects éthiques des etudes d'intervention [Ethical aspects of intervention studies]. Revue d'Épidémiologie et de Santé Publique1981; 29: 269-279.
22.
22. Nuremberg Military Tribunals. Trials of war criminals before the Nuremberg Military Tribunals under Control Council Law No. 10. Washington, DC: US Government Printing Office, 1949.
23.
23. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Belmont report: ethical principles and guidelines for the protection of human subjects of research. Washington, DC: Department of Health, Education, and Welfare, 1979.
24.
24. Clayton DG. Ethically optimised designs. British Journal of Clinical Pharmacology1982; 13: 469-480.
25.
25. Pocock SJ. Clinical trials: a practical approach. New York: John Wiley & Sons, 1983.
26.
26. Armitage P. The search for optimality in clinical trials (discussion). International Statistical Review1985; 53: 15-36.
27.
27. Block MR, Schaffner KF, Coulehan JL.Ethical problems of recording physician-patient interactions in family practice settings. Journal of Family Practice1985; 21: 467-472.
28.
28. Schaffner KF. Ethical problems in clinical trials. Journal of Medicine and Philosophy1986; 11: 297-315.
29.
29. Beauchamp TL, Childress JF. Principles of biomedical ethics, 2nd edn.New York: Oxford University Press, 1983.
30.
30. Kadane JB. Progress toward a more ethical method for clinical trials. Journal of Medicine and Philosophy1986; 11: 385-404.
31.
31. Pocock SJ. When to stop a clinical trial. British Medical Journal1992; 305: 235-240.
32.
32. Pocock SJ. Statistical and ethical issues in monitoring clinical trials. Statistics in Medicine1993; 12: 1459-1169.
33.
33. Freedman B. Equipoiseandthe ethicsof clinicalresearch. New England Journal of Medicine1987; 317: 141-145.
34.
34. Palmer CR. Ethics and statistical methodology in clinical trials. Journal of Medical Ethics1993; 19: 219-222.
35.
35. Freedman B, Shapiro SH. Ethics and statistics in clinical research: towards a more comprehensive examination. Journal of Statistical Planning and Inference1994; 42: 240-240.
36.
36. Schaffner KF. Ethically optimizing clinical trials. In Kadane JB ed. Bayesian methods and ethics in a clinical trial design. New York: John Wiley & Sons, 1996: 19-63.
37.
37. Kadane JB ed. Bayesian methods and ethics in a clinical trial design. New York: John Wiley & Sons, 1996.
38.
38. Armitage P. Attitudes in clinical trials. Statistics in Medicine1998; 17: 2675-2283.
39.
39. Palmer CR, Rosenberger WF. Ethics and practice: alternative designs for phase III randomized clinical trials. Controlled Clinical Trials1999; 20: 172-186.
40.
40. Beauchamp TL, Childress JF. Principles of biomedical ethics. 3rd edn.New York: Oxford University Press, 1989.
41.
41. Palmer CR. Ethics, data-dependent designs, and the strategy of clinical trials: time to start learning-aswe-go?Statistical Methods in Medical Research2002; 11: 381-402.
42.
42. Ashby D, Machin D. Stopping rules, interim analyses and data monitoring committees. British Journal of Cancer1993; 68: 1047-1150.
43.
43. Bather JA. Randomized allocation of treatments in sequential experiments. Journal of the Royal Statistical Society Series B Methodology1981; 43: 265-292.
44.
44. Boissel J-P. Impact of randomized clinical trials on medical practices. Controlled Clinical Trials1989; 10 (4 Suppl): 120S-134S.
45.
45. Jamart J. Combining the pragmatic attitude and the play-the-winner in controlled clinical trials. Biometrical Journal1985; 27: 199-203.
46.
46. Löwy I. “Nothing more to be done”: Palliative care versus experimental therapy in advanced cancer. Science in Context1995; 8: 209-229.
47.
47. Pullman D, Wang XK. Adaptive designs, informed consent, and the ethics of research. Controlled Clinical Trials2001; 22: 203-210.
48.
48. Senn S. Ethical considerations concerning treatment allocation in drug development trials. Statistical Methods in Medical Research2002; 11: 403-411.
49.
49. von Eickstedt K-W. Bewertung der vershiedenen Phasen der klinischen Prüfung [Valuation of the different phases of the clinical trial]. Münchener Medizinische Wochenschrift1983; 125: 21-25.
50.
50. von Eickstedt K-W. The ethical position of the attending physician in phase III of clinical investigations. International Journal of Clinical Pharmacology, Therapy and Toxicology1983; 21: 529-534.
51.
51. Fried C. Medical experimentation: personal integrity and social policy. Amsterdam: North-Holland Publishing Company, 1974.
